Article
Cell Biology
Ester Fagnano, Swati Pendharkar, Madyson Colton, Philip N. Jones, Marta Crespi Sallan, Tetyana Klymenko, Andrejs Braun, Christian Klein, Jamie Honeychurch, Eleanor J. Cheadle, Timothy M. Illidge
Summary: This study showed that contact between tumor cells and stromal cells inhibits the effector functions of Obinutuzumab, highlighting the potential for improved therapies targeting the microenvironment to enhance patient outcomes in B-cell malignancies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Oncology
Takaaki Fujimura, Yoriko Yamashita-Kashima, Natsumi Kawasaki, Shigeki Yoshiura, Naoki Harada, Yasushi Yoshimura
Summary: Retreatment with obinutuzumab in combination with chemotherapeutic agents is effective in CD20-positive obinutuzumab-induced direct-cell-death-resistant cells, showing significant antitumor effects in mouse xenograft models.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra, Anne T. Gelderloos, Daniella R. A. I. Berry, Nathalie J. Hijmering, Hendrik F. van Essen, Daphne de Jong, Martine E. D. Chamuleau, Sonja Zweegman, Esther C. W. Breij, Margaretha G. M. Roemer, Tuna Mutis
Summary: Epcoritamab showed potent activity against primary tumor cells of B-NHL patients, irrespective of prior treatments. The capacity of B-cell tumors to activate T-cells was heterogeneous and inversely associated with their expression levels of HVEM.
BLOOD CANCER JOURNAL
(2021)
Article
Multidisciplinary Sciences
Kathrin Klaesener, Julia Jellusova, Geoffroy Andrieux, Ulrich Salzer, Chiara Boehler, Sebastian N. Steiner, Jonas B. Albinus, Marco Cavallari, Beatrix Suess, Reinhard E. Voll, Melanie Boerries, Bernd Wollscheid, Michael Reth
Summary: CD20 regulates the nanoscale organization of receptors on resting B lymphocytes, and its disruption leads to B cell activation and internalization of membrane proteins.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Chemistry, Multidisciplinary
M. Tommy Gambles, Jiyuan Yang, Jindrich Kopecek
Summary: The concept of multi-targeted immunotherapeutic systems has revolutionized cancer immunotherapy by engaging the patient's immune system in various ways. The outcomes range from recruiting and activating immune cells upon recognizing cancer cells, to implementing a multi-pronged immune checkpoint blockade strategy, or achieving direct cancer cell death through engaging multiple cell surface receptors. This review focuses on the application of multi-specific immunotherapeutics for B cell malignancies, outlining diverse strategies, summarizing B cell receptor antigen targeting approaches, and discussing the challenges and future prospects of the field.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Immunology
Katrin Schoenfeld, Julia Harwardt, Jan Habermann, Adrian Elter, Harald Kolmar
Summary: This article presents a novel approach using specific antibody-drug conjugates to eliminate malignant B cells while maintaining a functional adaptive immune system, providing a new method for non-Hodgkin's lymphoma treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Alireza Poustforoosh, Sanaz Faramarz, Manica Negahdaripour, Hassan Hashemipour
Summary: B-cell Non-Hodgkin lymphomas are malignancies of lymphocytes, and CD20 is highly expressed on the cell surface of B-cells in NHL. Nanobodies (NBs), with low molecular weights, high specificity, and superior characteristics, can be used as alternatives to monoclonal antibodies (mAbs). In this study, an optimized NB was designed as a CD20 inhibitor with improved binding affinity to CD20. The optimized NB, designated as NB2, showed remarkable binding affinity to CD20 and could be considered as a potential CD20 inhibitor.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Sebastian Horner, Moustafa Moustafa-Oglou, Karin Teppert, Ilona Hagelstein, Joseph Kauer, Martin Pfluegler, Kristina Neumann, Hans-Georg Rammensee, Thomas Metz, Andreas Herrmann, Helmut R. Salih, Gundram Jung, Latifa Zekri
Summary: This article presents a novel approach to selectively induce apoptosis in lymphoma cells and autoreactive B cells using bispecific antibodies. The developed IgG-based bispecific antibodies show efficient depletion of malignant and autoreactive B cells in vitro and in vivo.
Article
Infectious Diseases
Akio Onishi, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Taku Tsukamoto, Takahiro Fujino, Akihiro Miyashita, Daichi Nishiyama, Kazuho Shimura, Hiroto Kaneko, Eri Kawata, Ryoichi Takahashi, Tsutomu Kobayashi, Hitoji Uchiyama, Nobuhiko Uoshima, Yoko Nukui, Yuji Shimura, Tohru Inaba, Junya Kuroda
Summary: The use of anti-CD20 monoclonal antibodies in B-cell lymphoma patients treated with B-cell depletion therapy can impair the antibody response to anti-SARS-CoV-2 vaccination. Predicting the antibody response is crucial during the COVID-19 pandemic to prevent the disease in these patients.
INFECTION AND DRUG RESISTANCE
(2023)
Article
Hematology
Steven Le Gouill, Herve Ghesquieres, Lucie Oberic, Franck Morschhauser, Herve Tilly, Vincent Ribrag, Thierry Lamy, Catherine Thieblemont, Herve Maisonneuve, Remy Gressin, Krimo Bouhabdallah, Corinne Haioun, Gandhi Damaj, Luc Fornecker, Reda Bouhabdallah, Pierre Feugier, David Sibon, Guillaume Cartron, Christophe Bonnet, Marc Andre, Loic Chartier, Philippe Ruminy, Francoise Kraeber-Bodere, Caroline Bodet-Milin, Alina Berriolo-Riedinger, Josette Briere, Jean-Philippe Jais, Thierry Jo Molina, Emmanuel Itti, Rene-Olivier Casasnovas
Summary: For transplant-eligible patients with untreated diffuse large B-cell lymphoma (DLBCL) and an age-adjusted International Prognostic Index (aaIPI) score >= 1, obinutuzumab is not superior to rituximab.
Article
Immunology
Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Marika Watanabe, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Taiji Koyama, Yoshinori Imamura, Naomi Kiyota, Hiroshi Matsuoka, Yasuko Mori, Hironobu Minami
Summary: Patients treated with anti-CD20 antibodies who failed two-dose vaccination had an insufficient response, but a third dose improved the seroconversion rate.
Article
Oncology
Anna Dalla Pieta, Elisa Cappuzzello, Pierangela Palmerini, Annavera Ventura, Andrea Visentin, Giuseppe Astori, Katia Chieregato, Valentina Mozzo, Omar Perbellini, Maria Chiara Tisi, Livio Trentin, Carlo Visco, Marco Ruggeri, Roberta Sommaggio, Antonio Rosato
Summary: The study suggests an adoptive immunotherapy approach that combines CIK cells and CD20 antibody as an effective therapeutic strategy for aggressive B-cell malignancies, which can be rapidly translated into clinical practice without the need for genetic modifications.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Andreas Mackensen, Fabian Mueller, Dimitrios Mougiakakos, Sebastian Boeltz, Artur Wilhelm, Michael Aigner, Simon Voelkl, David Simon, Arnd Kleyer, Luis Munoz, Sascha Kretschmann, Soraya Kharboutli, Regina Gary, Hannah Reimann, Wolf Roesler, Stefan Uderhardt, Holger Bang, Martin Herrmann, Arif Buelent Ekici, Christian Buettner, Katharina Maria Habenicht, Thomas H. Winkler, Gerhard Kroenke, Georg Schett
Summary: A study of five patients with refractory systemic lupus erythematosus treated with anti-CD19 CAR T cell therapy showed remission of SLE disease in all patients after 3 months, and long-term drug-free remission was maintained during follow-up.
Article
Biology
Zhaoqi Chen, Yan Liu, Nianci Chen, Haiyan Xing, Zheng Tian, Kejing Tang, Qing Rao, Yingxi Xu, Ying Wang, Min Wang, Jianxiang Wang
Summary: CD19 chimeric antigen receptor (CAR) T cells have shown success in acute lymphoblastic leukemia but have limited efficacy in other types of leukemia and lymphoma. This study constructed bispecific CAR-T cells targeting both CD19 and CD20 antigens, which demonstrated superior efficacy in eliminating lymphoma cells in vitro and in a mouse model. The loop2019 CAR structure showed the highest efficiency and potential for clinical treatment.
SCIENCE CHINA-LIFE SCIENCES
(2023)
Article
Immunology
Federica Calo, Lorenzo Onorato, Mariantonietta Pisaturo, Antonio Pinto, Loredana Alessio, Caterina Monari, Carmine Minichini, Manuela Arcamone, Alessandra Di Fraia, Luigi Atripaldi, Claudia Tiberio, Nicola Coppola
Summary: There is limited data regarding the effectiveness of anti-SARS-CoV-2 vaccine in immunocompromised patients. This report presents the virological and clinical characteristics of a patient with follicle center lymphoma who was infected by the SARS-CoV-2 Omicron variant despite receiving three doses of the BNT162b2 vaccine. The patient initially experienced remission due to early therapy with sotrovimab, but suffered a fatal relapse caused by the same viral strain.
Article
Radiology, Nuclear Medicine & Medical Imaging
Fabien Ricard, Bruce Cheson, Sally Barrington, Judith Trotman, Annette Schmid, Guenther Brueggenwerth, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Ron Korn
Summary: This article presents consensus recommendations on the consistent application of the Lugano classification in the field of lymphoma and imaging. The recommendations were obtained through meetings involving academic and industry experts and provide updates and clarifications on the technical considerations and scoring guidelines of the Lugano classification. These consensus recommendations aim to address inconsistencies and ambiguities encountered by end users during response evaluation and should be used alongside the 2014 Lugano classification as a companion guide.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Review
Hematology
Lorenzo Falchi, Santosha A. Vardhana, Gilles A. Salles
Summary: Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have undergone significant changes in the past two decades due to the introduction of highly active immunotherapies. Bispecific antibodies (BsAb) have emerged as a promising immunotherapeutic for B-NHL, with anti-CD20xCD3 BsAb showing remarkable single-agent activity. However, further research is needed to determine the optimal deployment of these drugs, ideal combination partners, strategies for minimizing toxicity, and pharmacodynamic biomarkers of response and resistance.
Review
Hematology
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M. H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. Park, James J. Wu, Rubina Siddiqi, John Reitan, Sally Wade, Gilles Salles
Summary: Relapsed Mantle cell lymphoma (MCL) has a poor prognosis and there is no standard treatment. This study examined the outcomes of salvage therapy in MCL patients who failed Bruton tyrosine kinase inhibitor (BTKi) therapy, showing shorter overall survival in this group compared to those who received post-BTKi therapy.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Hematology
David Qualls, Brandon S. Imber, Michelle Okwali, Paul A. Hamlin, Anita Kumar, Oscar B. Lahoud, Matthew J. Matasar, Ariela Noy, Colette Owens, Andrew D. Zelenetz, Victoria S. North, Heiko Schoeder, Ahmet Dogan, Gilles Salles, Joachim Yahalom, Lorenzo Falchi
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Catherine Thieblemont, Michal Szymczyk, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hubel, Corinne Haioun, Rene Olivier Casasnovas, Christian Schmidt, Kamal Bouabdallah, Vincent Ribrag, Lothar Kanz, Jan Durig, Bernd Metzner, David Sibon, Morgane Cheminant, Barbara Burroni, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Martin Dreyling
Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies for which the primary end point has already been reported. This study confirms the previously observed substantially prolonged time to treatment failure and shows an improvement in overall survival for patients with Mantle Cell Lymphoma. Some patients with MCL may be cured.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ana Alarcon Tomas, Joshua A. Fein, Shalev Fried, Jessica R. Flynn, Sean M. Devlin, Warren B. Fingrut, Theodora Anagnostou, Anna Alperovich, Nishi Shah, Ellen Fraint, Richard J. Lin, Michael Scordo, Connie Lee Batlevi, Michal J. Besser, Parastoo B. Dahi, Ivetta Danylesko, Sergio Giralt, Brandon S. Imber, Elad Jacoby, Meirav Kedmi, Arnon Nagler, M. Lia Palomba, Mikhail Roshal, Gilles A. Salles, Craig Sauter, Noga Shem-Tov, Avichai Shimoni, Joachim Yahalom, Ronit Yerushalmi, Gunjan L. Shah, Abraham Avigdor, Miguel-Angel Perales, Roni Shouval
Summary: Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common and associated with poor prognosis. Novel agents such as polatuzumab and lenalidomide may have potential as treatment options.
Letter
Oncology
David Qualls, Ariela Noy, David Straus, Matthew Matasar, Craig Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Salles, Anas Younes, Andrew D. Zelenetz, Connie Lee Batlevi
LEUKEMIA & LYMPHOMA
(2023)
Article
Hematology
Reid W. Merryman, Laure Michaud, Robert Redd, Patrizia Mondello, Hyesun Park, Gabriela Spilberg, Matthew Robertson, Eleanor Taranto, Gulrayz Ahmed, Matthew Chase, Erin Jeter, Inhye E. Ahn, Jennifer R. Brown, Jennifer Crombie, Matthew S. Davids, David C. Fisher, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O. Odejide, Erin M. Parry, Gilles Salles, Andrew D. Zelenetz, Philippe Armand, Heiko Schoeder, Heather Jacene
Summary: This study found that interim PET scans after 2-4 cycles of frontline chemoimmunotherapy can predict progression-free survival in follicular lymphoma patients, and may be used as a tool for response-adapted treatment strategies.
Editorial Material
Hematology
U. Vitolo, P. M. M. Frascione, F. Bonello
Summary: The study by Kambhampati et al. provides the first European perspective on the cost-effectiveness of pola-R- CHP as frontline treatment for DLBCL patients. However, the applicability of these results in other European settings is questionable, as Germany's access to cellular therapies in earlier lines may not be representative of other countries. The presented data should be re-assessed when long-term data from the POLARIX trial, including real-life data, are available. Additionally, further cost-effectiveness analyses in other European healthcare systems and specific patient subgroups are needed to offer a broader perspective on the potential role of pola-R- CHP in Europe.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Asma Beldi-Ferchiou, Jean-Philippe Jais, Herve Ghesquieres, Rene Olivier Casasnovas, Herve Tilly, Christophe Fruchart, Franck Morschhauser, Corinne Haioun, Julien Lazarovici, Aurore Perrot, Emmanuelle Nicolas-Virelizier, Gilles Salles, Nathalie Godard, Imen Zamali, Jean-Marc Schiano De Colella, Alexis Claudel, Bernadette Corront, Lucie Oberic, Josette Briere, Philippe Gaulard, Catherine Thieblemont, Marie-Helene Delfau-Larue
Summary: Low baseline NK-cell counts (NKCCs) in DLBCL patients are associated with poor prognosis. Lenalidomide maintenance does not affect the prognostic value of low NKCCs in DLBCL patients. Improving NK-cell function could be a potential therapeutic strategy to improve outcomes in DLBCL.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Sammara Chaubard, Amira Marouf, David Lavergne, Francois Lemonnier, Julien Rossignol, Aline Clavert, Remy Gressin, Guillaume Cartron, Agathe Waultier-Rascalou, Jacques Vargaftig, Gilles Salles, Emmanuel Bachy, Herve Ghesquieres, Olivier Tournilhac, Adrien Chauchet, Steven Le Gouill, Gandhi Damaj, Luc-Matthieu Fornecker, David Sibon, Lucie Oberic, Jean-Marie Michot, Philippe Gaulard, Olivier Hermine, Lucile Couronne, Arnaud Jaccard
Summary: We conducted a retrospective multi-center study to evaluate the efficacy of the MGAD regimen combined with 'sandwich' radiotherapy in patients with localized extranodal NK/T-cell lymphoma. The results showed high rates of complete remission and favorable progression-free and overall survival at 2 and 5 years. However, a significant proportion of patients experienced relapse and there were manageable side effects. Monitoring of asparaginase activity revealed drug inactivation in a considerable number of patients. Short-term MGAD chemoradiotherapy appears to be a viable treatment option for newly diagnosed patients with localized extranodal NK/T-cell lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Editorial Material
Hematology
Umberto Vitolo, Annalisa Chiappella
Correction
Oncology
Sonja I. Berndt, Joseph Vijai, Yolanda Benavente, Nicola J. Camp, Alexandra Nieters, Zhaoming Wang, Karin E. Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, Christine F. Skibola, Lindsay M. Morton, Angela R. Brooks-Wilson, Lauren R. Teras, Charles Breeze, Joshua Arias, Hans-Olov Adami, Demetrius Albanes, Kenneth C. Anderson, Stephen M. Ansell, Bryan Bassig, Nikolaus Becker, Parveen Bhatti, Brenda M. Birmann, Paolo Boffetta, Paige M. Bracci, Paul Brennan, Elizabeth E. Brown, Laurie Burdett, Lisa A. Cannon-Albright, Ellen T. Chang, Brian C. H. Chiu, Charles C. Chung, Jacqueline Clavel, Pierluigi Cocco, Graham Colditz, Lucia Conde, David V. Conti, David G. Cox, Karen Curtin, Delphine Casabonne, Immaculata De Vivo, Arjan Diepstra, W. Ryan Diver, Ahmet Dogan, Christopher K. Edlund, Lenka Foretova, Joseph F. Fraumeni, Attilio Gabbas, Herve Ghesquieres, Graham G. Giles, Sally Glaser, Martha Glenn, Bengt Glimelius, Jian Gu, Thomas M. Habermann, Christopher A. Haiman, Corinne Haioun, Jonathan N. Hofmann, Theodore R. Holford, Elizabeth A. Holly, Amy Hutchinson, Aalin Izhar, Rebecca D. Jackson, Ruth F. Jarrett, Rudolph Kaaks, Eleanor Kane, Laurence N. Kolonel, Yinfei Kong, Peter Kraft, Anne Kricker, Annette Lake, Qing Lan, Charles Lawrence, Dalin Li, Mark Liebow, Brian K. Link, Corrado Magnani, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Roger L. Milne, Thierry J. Molina, Alain Monnereau, Rebecca Montalvan, Kari E. North, Anne J. Novak, Kenan Onel, Mark P. Purdue, Kristin A. Rand, Elio Riboli, Jacques Riby, Eve Roman, Gilles Salles, Douglas W. Sborov, Richard K. Severson, Tait D. Shanafelt, Martyn T. Smith, Alexandra Smith, Kevin W. Song, Lei Song, Melissa C. Southey, John J. Spinelli, Anthony Staines, Deborah Stephens, Heather J. Sutherland, Kaitlyn Tkachuk, Carrie A. Thompson, Herve Tilly, Lesley F. Tinker, Ruth C. Travis, Jenny Turner, Celine M. Vachon, Claire M. Vajdic, Anke Van den Berg, David J. Van den Berg, Roel C. H. Vermeulen, Paolo Vineis, Sophia S. Wang, Elisabete Weiderpass, George J. Weiner, Stephanie Weinstein, Nicole Wong Doo, Yuanqing Ye, Meredith Yeager, Kai Yu, Anne Zeleniuch-Jacquotte, Yawei Zhang, Tongzhang Zheng, Elad Ziv, Joshua Sampson, Nilanjan Chatterjee, Kenneth Offit, Wendy Cozen, Xifeng Wu, James R. Cerhan, Stephen J. Chanock, Susan L. Slager, Nathaniel Rothman
Article
Cell Biology
Ester Fagnano, Swati Pendharkar, Madyson Colton, Philip N. Jones, Marta Crespi Sallan, Tetyana Klymenko, Andrejs Braun, Christian Klein, Jamie Honeychurch, Eleanor J. Cheadle, Timothy M. Illidge
Summary: This study showed that contact between tumor cells and stromal cells inhibits the effector functions of Obinutuzumab, highlighting the potential for improved therapies targeting the microenvironment to enhance patient outcomes in B-cell malignancies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Infectious Diseases
Tommaso Lupia, Elena Crisa, Alberto Gaviraghi, Barbara Rizzello, Alessia Di Vincenzo, Fabrizio Carnevale-Schianca, Daniela Caravelli, Marco Fizzotti, Francesco Tolomeo, Umberto Vitolo, Ilaria De Benedetto, Nour Shbaklo, Alessandro Cerutti, Piero Fenu, Vanesa Gregorc, Silvia Corcione, Valeria Ghisetti, Francesco Giuseppe De Rosa
Summary: Co-infections of Strongyloides and cytomegalovirus are rarely reported but have high morbidity and mortality in immunocompromised hosts. Most cases occur in male patients, especially in solid organ transplants and hematological or rheumatological diseases. Steroid treatment is common before the diagnosis of co-infections, and the treatment mortality rate is high.
TROPICAL MEDICINE AND INFECTIOUS DISEASE
(2023)
